Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Exelisis
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01835145
First received: April 16, 2013
Last updated: November 30, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: November 2017 (Final data collection date for primary outcome measure)